Skip Navigation LinksHome > July 2013 - Volume 47 - Issue > An Update on Clinical Trials in the Treatment of Advanced He...
Journal of Clinical Gastroenterology:
doi: 10.1097/MCG.0b013e31827d77a2
Presentations

An Update on Clinical Trials in the Treatment of Advanced Hepatocellular Carcinoma

Lee, Jean K. MD, PhD*; Abou-Alfa, Ghassan K. MD*,†

Collapse Box

Abstract

Despite the successful FDA approval of sorafenib as the standard of care therapy in patients with advanced hepatocellular carcinoma (HCC), its clinical benefits have been modest. The mortality rate remains high and prognosis poor for patients with advanced-stage HCC. The exact mechanism of sorafenib in the treatment of HCC and its resistance at the molecular levels are largely unknown. There are no other treatment options in first-line therapy and there is currently no standard of care second-line therapies available. Thus, there is a critical need for novel therapeutic approaches for the treatment of advanced HCC, and thus a clear justification for the already reported, currently ongoing, and planned clinical trials.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.